Australia Lung Cancer Screening Market Forecast to 2030 - Country Analysis by Cancer Type [Non-Small Cell Lung Cancer and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography, Chest X-Ray, Liquid Biopsy, and Others], Age Group, and End User

The Australia lung cancer screening market size is expected to grow from US$ 2.74 million in 2022 to US$ 6.12 million by 2030; it is estimated to record a CAGR of 10.6% from 2022 to 2030.

The Australia lung cancer screening market growth is attributed to the increasing Incidence of lung cancer and rising government support. However, uncertainties related to lung cancer screening trial with LDCT is hampering the growth of the Australia lung cancer screening market.

Lung cancer screening is a process used to detect lung cancer in otherwise healthy people with a high risk of lung cancer. Lung cancer screening is recommended for older adults who are long time smokers and who don't have any signs or symptoms of lung cancer. Doctors use a LDCT scan of the lungs to look for lung cancer. If lung cancer is detected early, it's more likely to be cured with treatment.

Structured Lung Cancer Screening Program is expected to provide the opportunities in the forecast period.

Australia faces unique challenges with lung cancer screening programs. A few examples of population-based Australian screening programs are 'BreastScreen,' the 'National Bowel Cancer Screening Program,' and the 'National Cervical Screening Program.' Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Further, the International Association for the Study of Lung Cancer (IASLC) recommends implementing feasibility screening programs in the country without participating in lung cancer screening studies. These programs involve smoking cessation initiatives, standardized algorithms for selecting and managing screening participants, and specialist multidisciplinary teams to manage participants with positive screening results. Therefore, the implementation of structured lung cancer screening programs in the country is expected to be a lucrative opportunity in the Australia lung cancer screening market during the forecast period.

Australia Lung Cancer Screening Market - Test Type Insights

Based on cancer type, the Australia lung cancer screening market is bifurcated into NSCLC and small cell lung cancer. The NSCLC segment accounted for the largest market share in 2022 and is expected to grow at a CAGR of 10.3% during the forecast period. The market position of this segment is due to the rising cases of NSCLC in Australia. NSCLC develops more slowly than small cell lung cancer. It usually spreads to other parts of the patient's body by the time it is diagnosed. Therefore, early diagnosis and treatment are crucial. According to National Foundation for Cancer Research, NSCLC accounts for nearly 9 out of every 10 diagnoses. As per the same source, large-cell undifferentiated carcinoma lung cancer accounts for approximately 10-15% of all NSCLC diagnoses.

Based on technology, the Australia lung cancer screening market is segmented into LDCT, chest X-ray, liquid biopsy, and others. The chest X-ray segment accounted for the largest market share in 2022, however, the LDCT is expected to grow at a CAGR of 11.9% during the forecast period.

Based on age group, the Australia lung cancer screening market is bifurcated into 50 & older and below 50. The 50 & older segment accounted for the largest market share in 2022, however, the below 50 is expected to grow at a CAGR of 11.3% during the forecast period.

Based on end user, the Australia lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment accounted for the largest market share in 2022, however, the others is expected to grow at a CAGR of 11.1% during the forecast period.

Australia Lung Cancer Screening Market - Recent Developments:

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the Australia lung cancer screening market. A few recent key market developments are listed below:

In June 2022, Royal Philips teamed up with Biodesix, Inc. to incorporate the results of Biodesix’s Nodify Lung blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data along with the radiologic and patient history data currently used to determine treatment decisions can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator.

In August 2022, Intelerad Medical Systems acquired of PenRad Technologies, Inc., a software provider for enhancing breast imaging and lung screening productivity. The acquisition has expanded Intelerad’s product offerings for mammography and lung analytics, optimizing workflow for radiologists and boosting patient health outcomes.